Printer Friendly

Hopes dashed.

An anti-herpes drug researchers were counting on to reduce susceptibility to HIV infection doesn't offer any protection, according to results presented at the 15th annual Conference on Retroviruses and Opportunistic Infections this February.

In the study more than 3,000 participants with herpes simplex virus 2 were given either 400 milligrams of the anti-herpes medication acyclovir or a placebo twice daily. Results showed a 3.9% HIV incidence rate (75 cases) among participants who received acyclovir, compared to a 3.3% HIV incidence rate (64 cases) among the placebo group.

The research was considered particularly important because having herpes, one of the most common sexually transmitted diseases worldwide, almost triples a person's odds of acquiring HIV.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Health News You Should Know; herpes research counting on to reduce susceptibility to HIV infection
Author:Henneman, Todd
Publication:The Advocate (The national gay & lesbian newsmagazine)
Article Type:Brief article
Geographic Code:1USA
Date:Apr 8, 2008
Previous Article:Should the Swiss stick to army knives and chocolate?
Next Article:Gays and violence.

Related Articles
Some HIV-infected people forgo AZT.
Women and HIV.
SMART: background, concepts, and design.
The "ABC to Z" approach: condoms are one element in a comprehensive approach to HIV/STI prevention. (Introduction).
Family planning and HIV service integration: potential synergies are recognized.
Women's health issues: the personal, the medical, and the political.
Does hormonal contraception speed HIV progression?
People with herpes at higher risk for HIV.
New study points to high STI rates among teens, major disparities among population groups.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters